Clinical improvement in eosinophilic oesophagitis
| Visit | Global improvement | Mepolizumab (n = 5) n (%) | Placebo (n = 6) n (%) |
| Week 4 | Much worse | 0 | 1 (17%) |
| Minimally worse | 0 | 1 (17%) | |
| No change | 2 (40%) | 1 (17%) | |
| Minimally improved | 2 (40%) | 1 (17%) | |
| Much improved | 1 (20%) | 1 (17%) | |
| Very much improved | 0 | 1 (17%) | |
| Week 13 | Much worse | 0 | 0 |
| Minimally worse | 0 | 0 | |
| No change | 3 (60%) | 5 (83%) | |
| Minimally improved | 0 | 1 (17%) | |
| Much improved | 2 (40%) | 0 | |
| Very much improved | 0 | 0 | |
| Week 21 | Much worse | 1 (20%) | 0 |
| Minimally worse | 1 (20%) | 0 | |
| No change | 3 (60%) | 5 (83%) | |
| Minimally improved | 0 | 0 | |
| Much improved | 0 | 1 (17%) | |
| Very much improved | 0 | 0 | |
| Early withdrawal during long-term follow-up | Much worse | 1 (100%) | 2 (100%) |
| Minimally worse | 0 | 0 | |
| No change | 0 | 0 | |
| Minimally improved | 0 | 0 | |
| Much improved | 0 | 0 | |
| Very much improved | 0 | 0 |